Literature DB >> 8182699

The desferrithiocin pharmacophore.

R J Bergeron1, C Z Liu, J S McManis, M X Xia, S E Algee, J Wiegand.   

Abstract

The (S)-desferrithiocin (DFT) skeleton is shown to be a useful pharmacophore on which to design orally effective iron chelators. While the study clearly indicates that formal reduction of the desazadesmethyldesferrithiocin thiazoline to a thiazolidine (6), expansion of the desmethyldesferrithiocin thiazoline to a thiazine (7), or substitution of the thiazoline sulfur of of desazedes-methyldesferrithiocin by an oxygen (8 and 9) lead to a substantial loss of activity, conversion of (S)-desmethyldesferrithiocin (1) to an N-methylhydroxamate (4) or to the hexacoordinate dihydroxamate ligand (5) results in active compounds. This investigation thus demonstrates which structural components of the siderophore are required for iron clearance after oral administration and suggests the use of the desferrithiocin platform as a vector for other chelators.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8182699     DOI: 10.1021/jm00036a005

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  Prevention of acetic acid-induced colitis by desferrithiocin analogs in a rat model.

Authors:  Raymond J Bergeron; Jan Wiegand; William R Weimar; John Nhut Nguyen; Charles A Sninsky
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

Review 2.  Desferrithiocin: a search for clinically effective iron chelators.

Authors:  Raymond J Bergeron; Jan Wiegand; James S McManis; Neelam Bharti
Journal:  J Med Chem       Date:  2014-09-10       Impact factor: 7.446

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.